Why precision oncology may be poised for a reset: a conversation with Sona Nanotech

Cancer has quietly become the pharmaceutical industry’s most lucrative disease area. In 2024 alone, global cancer drug sales exceeded $200 billion, making oncology the single largest revenue category in biopharma, well ahead of even the fast-growing obesity drug market. Yet behind the blockbuster numbers and steady stream of approvals, a more troubling reality is emerging. Many of today’s most profitable cancer drugs do not meaningfully extend patients’ lives. A recent Bloomberg investigation underscored th ...